学术报告

        2008年10月27日，美国Eidogen-Sertanty 公司CEO，世界知名生物和化学信息学家Steven Muskal博士将来访并作学术报告。

Exercising receptor-site similarity within the Proteome:

From Off-Target Identification to Ligand Scaffold Hopping

报告人：Steven Muskal (Ph.D., CEO)

Eidogen-Sertanty, Inc. （美国）

主持人：姚建华   博士

地点：图书馆楼长恭厅，时间：2008年10月27日（星期一）上午8:30

 欢迎大家参加！

Steven Muskal, Ph.D., CEO,

Eidogen-Sertanty, Inc.

Dr. Steven Muskal, founder of Sertanty, Inc. and Chief Executive Officer of Eidogen-Sertanty, has over 17 years of technology development and marketing experience in the biopharmaceutical community. Prior to establishing Sertanty, Dr. Muskal served as Vice President of Informatics for Libraria, Inc., helping to secure financing while responsible for technology development and operational activity. Prior to joining Libraria, he served as Unit Director at the Affymax Research Institute and as a member of the Glaxo Wellcome Scientific Computing Board. At Affymax, Dr. Muskal directed departments focusing on advanced technologies in parallel synthesis, lead optimization (ADME), and research computing. Previously, Dr. Muskal was a Product Manager, Senior Scientist, and Applications Scientist at MDL Information Systems, where he was responsible for the design, development, and marketing of combinatorial chemistry software, and for a worldwide technical marketing network of product specialists. Dr. Muskal received his Doctorate in Biophysical Chemistry from the University of California, Berkeley and his B.Sc. in Engineering Chemistry and Computer Science from the Colorado School of Mines. He is an avid sportsman and triathlete.